PRESIDENT ENDOCRINE TECHNOLOGY, LLC NY, New York, United States
Abstract Text: Problem: aTypical Hemolytic Uremia Syndrome (aHUS) is an extremely rare disease that contribute to life threatening disease. The human CFHR–Factor H gene cluster encodes are emerging complement and immune modulators. (Peter F. Zipfel, Thorsten Wiech, [...], and Christine Skerka "CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy" Published online 2020 Jan 24. doi: 10.1681/ASN.2019050515 J Am Soc Nephrol. 2020 Feb; 31(2): 241–25).
Results: The underlying disease is due to hyper activation of Complement and Coagulation cascade. Since both pathways can be blocked by proximal inhibition of complement system, Factor D inhibition offer an attractive molecular target for therapy. Discussions: Sulfonic polymer and its formulation methods are advanced as therapy of aHUS for better therapeutic outcome.
